Sepsis is the 10th leading cause of mortality in high-income countries with steadily rising incidence rates, caused by an over-reaction of the immune system to invasive pathogens. Mortality is a consequence of the complex host response with both the initial cytokine storm, as well as secondary immune suppression. Both the canonical and non-canonical inflammasome pathways through activation of caspases-1 and caspase-11 (caspase-4 in humans), respectively, are essential for mediating the responses to cytosolic pathogens and their PAMPS, including LPS, leading to pyroptosis and release of cytokines and danger signals. The canonical pathway is activated by cytosolic PRRs, including NLRP3. Assembly and signaling of the NLRP3 inflammasome is dependent on the PYRIN domain (PYD)-PYD interaction between NLRP3 and the adaptor ASC. The non-canonical pathway responds to cytosolic LPS and Gram-negative bacteria escaping the phagosome with pyroptosis, and engages the canonical NLRP3 inflammasome for cytokine release for host defense. However, defects in termination and uncontrolled activity results in excessive systemic inflammation and is linked to inflammatory and immune diseases. Hereditary mutations in NLRP3 cause Cryopyrinopathies (CAPS), a systemic inflammatory disease, which can be recapitulated in mice. Inflammasome particles are also released by M? and act as danger signals to further perpetuate inflammation to bystander cells, and these particles are found in sera in inflammatory disease patients and during bacterial infection and are thought to be responsible for the persistent and chronic responses. Thus, regulation/resolution of inflammasome responses is of utmost importance for maintaining homeostasis, but the molecular mechanisms are poorly understood. We discovered the PYD-only protein (POP)1 and established the POP family of inflammasome inhibitors, which are present in humans, but are lacking from mice and their endogenous functions have not been elucidated. We therefore developed a novel mouse model to study POP1 in vivo. We identified POP1 as a first key regulator for both the canonical and non- canonical inflammasomes as well as the bystander cell response during systemic inflammatory disease, discovered derailed expression of POP1 in human patients, and the objective of this application is therefore to elucidate the molecular mechanism in human and mouse macrophages and in vivo. We expect that the uncovered molecular mechanisms of this inflammasome pathway regulation will be widely applicable to other inflammasomopathies and infections and therefore positively affect human health.

Public Health Relevance

Sepsis is the 10th leading cause of mortality in high-income countries with incidence rates steadily on the rise, where the septic cytokine storm is mediated through release of cytokines, danger signals and induction of pyroptosis by the canonical and non-canonical inflammasomes, and these pathways also cause other systemic inflammatory diseases, including Cryopyrinopathy and danger signal-induced inflammation. We discovered the first inhibitor acting on both inflammasome pathways, which protects from the lethal consequences of experimental sepsis, Cryopyrinopathy and ASC danger signal-induced inflammation, and propose to study the molecular mechanism by which this inhibitor exerts protection and will further explore a novel treatment approach based on this inhibitor. We therefore expected to positively affect human health and to significantly advance our understanding of the pathology of sepsis and related systemic inflammatory diseases, and the derailed innate immune mechanism that contribute to their pathology.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI120625-05
Application #
9888298
Study Section
Immunity and Host Defense (IHD)
Program Officer
Minnicozzi, Michael
Project Start
2015-12-01
Project End
2020-11-30
Budget Start
2019-12-01
Budget End
2020-11-30
Support Year
5
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Cedars-Sinai Medical Center
Department
Type
DUNS #
075307785
City
Los Angeles
State
CA
Country
United States
Zip Code
90048
Chu, Lan H; Indramohan, Mohanalaxmi; Ratsimandresy, Rojo A et al. (2018) The oxidized phospholipid oxPAPC protects from septic shock by targeting the non-canonical inflammasome in macrophages. Nat Commun 9:996
Indramohan, Mohanalaxmi; Stehlik, Christian; Dorfleutner, Andrea (2018) COPs and POPs Patrol Inflammasome Activation. J Mol Biol 430:153-173
Bhattacharyya, Swati; Wang, Wenxia; Qin, Wenyi et al. (2018) TLR4-dependent fibroblast activation drives persistent organ fibrosis in skin and lung. JCI Insight 3:
Viaud, Manon; Ivanov, Stoyan; Vujic, Nemanja et al. (2018) Lysosomal Cholesterol Hydrolysis Couples Efferocytosis to Anti-Inflammatory Oxysterol Production. Circ Res 122:1369-1384
Ratsimandresy, Rojo A; Chu, Lan H; Khare, Sonal et al. (2017) The PYRIN domain-only protein POP2 inhibits inflammasome priming and activation. Nat Commun 8:15556
Ratsimandresy, Rojo A; Indramohan, Mohanalaxmi; Dorfleutner, Andrea et al. (2017) The AIM2 inflammasome is a central regulator of intestinal homeostasis through the IL-18/IL-22/STAT3 pathway. Cell Mol Immunol 14:127-142
Khare, Sonal; Radian, Alexander D; Dorfleutner, Andrea et al. (2016) Measuring NLR Oligomerization I: Size Exclusion Chromatography, Co-immunoprecipitation, and Cross-Linking. Methods Mol Biol 1417:131-43
de Almeida, Lucia; Dorfleutner, Andrea; Stehlik, Christian (2016) In vivo Analysis of Neutrophil Infiltration during LPS-induced Peritonitis. Bio Protoc 6:
de Almeida, Lucia; Dorfleutner, Andrea; Stehlik, Christian (2016) ASC-particle-induced Peritonitis. Bio Protoc 6:
Dorfleutner, Andrea; Stehlik, Christian (2016) A dRAStic RHOAdblock of Pyrin inflammasome activation. Nat Immunol 17:900-2

Showing the most recent 10 out of 11 publications